Breast cancer prevention by short-term inhibition of TGFβ signaling.
Maša AlečkovićSimona CristeaCarlos R Gil Del AlcazarPengze YanLina DingEthan D KropNicholas W HarperErnesto Rojas JimenezDonghao LuAnushree C GulvadyPierre FoidartMarco SeehawerBenedetto DiciaccioKatherine C MurphyJason PyrdolJayati AnandKodie GarzaKai W WucherpfennigRulla M TamimiFranziska MichorKornelia PolyakPublished in: Nature communications (2022)
Cancer prevention has a profound impact on cancer-associated mortality and morbidity. We previously identified TGFβ signaling as a candidate regulator of mammary epithelial cells associated with breast cancer risk. Here, we show that short-term TGFBR inhibitor (TGFBRi) treatment of peripubertal ACI inbred and Sprague Dawley outbred rats induces lasting changes and prevents estrogen- and carcinogen-induced mammary tumors, respectively. We identify TGFBRi-responsive cell populations by single cell RNA-sequencing, including a unique epithelial subpopulation designated secretory basal cells (SBCs) with progenitor features. We detect SBCs in normal human breast tissues and find them to be associated with breast cancer risk. Interactome analysis identifies SBCs as the most interactive cell population and the main source of insulin-IGF signaling. Accordingly, inhibition of TGFBR and IGF1R decrease proliferation of organoid cultures. Our results reveal a critical role for TGFβ in regulating mammary epithelial cells relevant to breast cancer and serve as a proof-of-principle cancer prevention strategy.
Keyphrases
- single cell
- breast cancer risk
- rna seq
- papillary thyroid
- transforming growth factor
- high throughput
- endothelial cells
- squamous cell
- induced apoptosis
- cell therapy
- type diabetes
- genome wide
- gene expression
- pi k akt
- transcription factor
- intellectual disability
- cell death
- coronary artery disease
- insulin resistance
- diabetic rats
- lymph node metastasis
- cardiovascular events
- combination therapy
- glycemic control
- growth hormone
- cell fate